Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...

Novo Nordisk stock took a big hit early Tuesday after the Danish weight-loss drugmaker unexpectedly cut its full-year guidance for the U.S.It also announced a new CEO, appointing an insider to lead ...

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

* Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new ...